At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 336 enrolled
Drug / intervention
MK-0954A +4 moredrug
Likely dose
Placebo to losartan 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Active-comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954A in Japanese Patients With Essential Hypertension Uncontrolled With the High Dose of Losartan Potassium
In Brief
A Phase 3 clinical trial evaluating MK-0954A, Losartan, and 3 other interventions for Hypertension. Completed, enrolled 336 participants.
Detailed Summary
This study is being conducted to evaluate the efficacy of MK-0954A in essential hypertension participants who are not adequately controlled with losartan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartMar 2011
Primary CompletionFeb 2012
TodayJul 2026
First PostedMar 2, 2011
Enrollment StartMar 29, 2011
Primary CompletionFeb 7, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.3 years ago
Interventions
MK-0954Adrug
Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
Losartandrug
Tablet containing losartan potassium (100 mg), once daily
Placebo to MK-0954Adrug
Placebo tablet to match MK-0954A, once daily
Placebo to losartan 100 mgdrug
Placebo tablet to match losartan 100 mg, once daily
Placebo to losartan 50 mgdrug
Placebo tablet to match losartan 50 mg, once daily